A recent study looked at the use of a combination of immunotherapy plus cabozantinib as a second treatment for patients with metastatic kidney cancer compared to cabozantinib alone in the real world.

The study used data from a large real-world US-based database and looked at patients diagnosed with metastatic kidney cancer who were treated with any immunotherapy-based combination as a first treatment followed by a second treatment with either cabozantinib alone or in combination with immunotherapy.

There were 348 patients in the study. However, this study showed no additional benefit of adding immunotherapy to cabozantinib compared to cabozantinib alone as a second treatment after immunotherapy as a first treatment. These results from real-world patients strengthen the evidence regarding the uselessness of treating patients with immunotherapy as a second treatment after already having been treated with immunotherapy as a first treatment.

Read more in UroToday here